DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Havrix (Hepatitis A Vaccine (Inactivated)) - Drug Interactions, Contraindications, Overdosage, etc



HAVRIX drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.


Hypersensitivity to any component of the vaccine, including neomycin, is a contraindication (see DESCRIPTION). This vaccine is contraindicated in patients with previous hypersensitivity to any hepatitis A-containing vaccine.


  1. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease. Baltimore, Williams & Wilkins; 1991:14-20.
  2. Dienstag JL, Routenberg JA, Purcell RH, et al. Foodhandler-associated outbreak of hepatitis type A. An immune electron microscopic study. Ann Intern Med 1975;83:647-650.
  3. Mackowiak PA, Caraway CT, Portnoy BL. Oyster-associated hepatitis: Lessons from the Louisiana experience. Am J Epidemiol 1976;103(2):181-191.
  4. Woodson RD, Clinton JJ. Hepatitis prophylaxis abroad. Effectiveness of immune serum globulin in protecting Peace Corps volunteers. JAMA 1969;209(7):1053-1058.
  5. Krugman S, Giles JP. Viral hepatitis. New light on an old disease. JAMA 1970;212(6):1019-1029.
  6. Mosley JW. Hepatitis types B and non-B. Epidemiologic background. JAMA 1975;233(9):967-969.
  7. Hadler SC, Erben JJ, Francis DP, et al. Risk factors for hepatitis A in day-care centers. J Infect Dis 1982;145(2):255-261.
  8. Shapiro CN, Shaw FE, Mandel EJ, et al. Epidemiology of hepatitis A in the United States. In Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease. Baltimore, Williams & Wilkins; 1991:71-76.
  9. Centers for Disease Control. Protection against viral hepatitis: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990;39(RR-2):1-26.
  10. Lemon SM. Type A viral hepatitis: New developments in an old disease. N Engl J Med 1985;313(17):1059-1067.
  11. Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-226.
  12. Hollinger FB, Ticehurst J. Hepatitis A virus. In Hollinger FB, Robinson WS, Purcell RH, Gerin JL, Ticehurst J, eds. Viral hepatitis. New York, Raven Press, 1990:1-37.
  13. Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, et al. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 1986;154(2):231-237.
  14. Chiriaco P, Gaudalupi C, Armigliato M, et al. Polyphasic course of hepatitis type A in children. J Infect Dis 1986;153(2):378-379.
  15. Data on file, GlaxoSmithKline.
  16. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271(17):1328-1334.
  17. McMahon BJ, Beller M, Williams J, et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996;150:733-739.
  18. Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1998;47(RR-1):100.
  19. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(RR-12):26-29.
  20. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42 (RR-4):1-18.
  21. Centers for Disease Control. Vaccine Adverse Event Reporting System -- United States. MMWR 1990;39(41):730-733.
  22. Centers for Disease Control and Prevention. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. MMWR 2002;51(RR-2):23-24.

Manufactured by GlaxoSmithKline Biologicals, Rixensart,

Belgium, US License No. 1617

Distributed by GlaxoSmithKline,

Research Triangle Park, NC 27709

HAVRIX and TIP-LOK are registered trademarks of GlaxoSmithKline

SAFETYGLIDE is a trademark of Becton, Dickinson and Company.

©2003, GlaxoSmithKline. All rights reserved.

August 2003/HA:L17

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017